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Article Summary:  Even in previously vaccine-naïve populations, pre-existing immunity, such as that 
potentially arising from prior exposure to natural infection, may influence vaccine virus recovery and 
immune responses following receipt of a live attenuated influenza vaccine.  [33/40 words] 
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciy1004/5210472 by London School of H
ygiene & Tropical M
edicine user on 11 D
ecem
ber 2018
 2 
 
Abstract 
Background.  In a 2012 phase II clinical trial (NCT01625689), 300 Bangladeshi children aged 24 to 59 months 
with no prior influenza vaccine exposure were randomized to receive a single dose of intra-nasally administered 
trivalent Russian-backbone live attenuated influenza vaccine (LAIV) or placebo.  Protocol-defined analyses, 
presented in the companion manuscript, demonstrate decreased viral detection and immunogenicity for 
A/H1N1pdm09 relative to the A/H3N2 and B strains.  This post-hoc analysis of the trial data aims to investigate 
the LAIV strain differences by testing the hypothesis that pre-existing immunity may influence viral recovery and 
immune responses after LAIV receipt.   
Methods.  We used logistic regressions to evaluate the relations between markers of pre-existing immunity 
(i.e., hemagglutination inhibition (HAI), microneutralization, and IgA and IgG antibodies) and LAIV viral recovery 
in the week post-vaccination.  We then tested for potential effect modification by baseline HAI titers (i.e., <10 
versus ≥10) and week 1 viral recovery on the LAIV-induced serum and mucosal immune responses measured 
between days 0 and 21 post-vaccination.   
Results.  Higher levels of pre-existing immunity to influenza A/H3N2 and B were strongly associated with 
strain-specific prevention of viral shedding upon LAIV receipt.  While evidence of LAIV immunogenicity was 
observed for all three strains, the magnitudes of immune responses were most pronounced in children with no 
evidence of pre-existing HAI and in those with detectable virus. 
Conclusion.  The results provide evidence for a bidirectional association between viral replication and 
immunity and underscore the importance of accounting for pre-existing immunity when evaluating virologic and 
immunologic responses to LAIVs.  
 
Keywords:  influenza vaccine; humoral immunity; mucosal immunity; immunogenicity  
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Introduction 
 Owing to the ease of their intranasal administration and relatively low cost, live attenuated influenza 
vaccines (LAIVs) have the potential to be valuable tools for seasonal and pandemic influenza prevention, 
particularly in low-resource settings [1]. Nevertheless, a key challenge for LAIVs is that they have highly variable 
effectiveness [2], which may be modulated by construct-related differences (e.g., similarity to circulating influenza 
viruses or inherent variation in the extent of attenuation of recombinant viruses) and host-specific factors (e.g., 
age and health conditions). Whereas humoral, mucosal and cell-mediated immunologic readouts have been 
found to be associated with LAIV receipt in some cases [3-5], no specific combination of immune parameters 
has been consistently shown to be a true correlate of protection for LAIVs against influenza virus infection [6, 
7].  Accumulating evidence indicates that an underlying driver of the heterogeneity in immunologic responses to 
influenza vaccines in children may in fact be their prior exposure to naturally occurring infections or other 
influenza vaccines [8-10].  A better understanding of the effects of pre-existing immunity on post-vaccination 
endpoints is needed to improve LAIV clinical evaluation and performance. 
Using data from a 2012 Phase II, randomized, double-blind, parallel group, placebo-controlled trial of a 
seasonal trivalent Russian-backbone LAIV (NCT01625689), this investigation aims to shed new light on the 
interplay between pre-existing immunity, vaccine virus detection, and LAIV-induced humoral and mucosal 
immune responses.  For the trial, 300 healthy, influenza vaccine-naïve children aged 24 to 59 months residing in 
Dhaka, Bangladesh, were randomized 1:1 to receive a single intra-nasal dose of a placebo control (Lot 
E9001PCB) or an A/Leningrad and B/USSR-backbone vaccine produced by the Serum Institute of India (Pune, 
India) [11] containing the WHO-recommended Northern Hemisphere influenza vaccine formulation for the 
2011-2012 season (i.e., A/California/7/2009 (H1N1)pdm09-like virus, A/Victoria/361/2011 (H3N2)-like virus, and 
B/Wisconsin/1/2010-like virus) [12].  A companion study by Lewis and colleagues reports the protocol-defined 
analyses demonstrating that viral detection and immune responses in the LAIV recipients differed by vaccine 
strains, with no A/H1N1pdm09 viral recovery as well as markedly decreased immunogenicity observed for 
A/H1N1pdm09 relative to the A/H3N2 and B strains [13].  Of note, previous work in Bangladesh has 
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demonstrated a significant impact of influenza illness in young children [14], with a notable penetration of 
A/H1N1pdm09 virus with its initial circulation in Dhaka [15]. The post-hoc investigation reported here builds on 
the work by Lewis and colleagues by assessing whether children’s strain-specific pre-existing immunity may 
influence the odds of vaccine virus detection in the week after vaccination and whether this pre-existing 
immunity, as well as nasopharyngeal viral replication, may modify LAIV-induced serum and mucosal immune 
responses measured in the 21 days post-vaccination.   
 
Methods 
Study design & laboratory procedures 
The study design and laboratory procedures are detailed in the companion manuscript [13].  Briefly, 
nasopharyngeal wash (NPW) specimens were collected from the children on trial days 0, 2, 4, 7, and 21 and 
stored frozen at -80°C; serum samples were collected on days 0 and 21 and stored frozen at -20°C.  The origin 
of identified strains (i.e., vaccine or wild-type) were confirmed in NPW specimens by reverse transcription 
polymerase chain reaction (rRT-PCR) [16].  Serum neutralizing antibodies against A/H1N1pdm09, A/H3N2, and 
B influenza were measured using hemagglutination inhibition (HAI) and microneutralization (MN) assays; titers of 
strain-specific serum immunoglobulin (Ig) G and IgA were quantified using enzyme-linked immunosorbent assays 
(ELISAs) [17, 18].  Titers of strain-specific mucosal IgA were quantified using kinetic ELISAs and normalized 
relative to the total specimen IgA [3, 4]. Out of the total of 300 participants, the 290 participants who had 
evaluable (i.e., sample received and considered valid) rRT-PCR typing of NPW specimens for each of the three 
time points in the week following vaccination (i.e., days 2, 4, and 7) were selected for inclusion in the analytical 
cohort for the current investigation [16].    
Ethics & role of the funding source 
The study was approved by the Committee for the Protection of Human Subjects at Dartmouth College 
(Hanover, NH, USA), the Western Institutional Review Boards (Olympia, WA, USA), and the local ethical 
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review board of International Centre for Diarrheal Disease Research, Bangladesh (Dhaka, Bangladesh) and was 
conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation 
guideline for Good Clinical Practice, and the codes and regulation of the United States and Bangladesh regarding 
research on human subjects.  The initial consenting included provisions for the use of samples in future 
influenza-related studies.   
Statistical approaches 
Pairwise correlations between baseline (i.e., trial day 0, prior to vaccination) levels of strain-specific 
serum and mucosal immune markers were estimated in the full analytical cohort with Spearman’s rank 
correlation coefficients and were visualized in matrices using the ‘corrplot’ R package, version 0.77 [19].  LAIV 
recipients were categorized as either ‘shedding-positive’ or ‘shedding-negative’ based on their A/H3N2 and B 
viral detection status (i.e., by whether any or no virus was detected from NPW specimens on days 2, 4, and 7 
after LAIV receipt); of note, no A/H1N1pdm09 shedding was detected in the NPW specimens on days 2, 4, and 
7 after LAIV receipt.  The associations between baseline immunity to A/H3N2 and B influenza (i.e., indicated by 
tertile of the strain-specific immune marker on trial day 0) and the odds of being shedding-negative were 
investigated using logistic regressions.  In order to allow the effect sizes to be compared informatively across any 
pair of tertiles and without depending on the precision within an arbitrarily selected baseline group, 95% 
confidence intervals (CIs) were estimated from floated variances [20].  The results were visualized by plotting 
the odds ratio and 95% CIs on the y-axis versus the geometric mean for each tertile of immune marker on the 
x-axis.  Cross-sectional differences in the log2 A/H3N2- and B-specific immune marker levels on trial days 0 and 
21 were compared between shedding-negative and shedding-positive groups using t-tests.  For all three strains, 
immune responses following LAIV receipt were visualized in the placebo, LAIV shedding-negative, and LAIV 
shedding-positive groups using scatterplots; P values were calculated separately within each treatment/shedding 
group using paired t-tests comparing the log2 titers on trial days 0 and 21.  Density plots were used to visualize 
the distributions of differences in the log2 serum and mucosal antibody titers between trial days 0 and 21 by 
immunoassay, influenza strain, treatment/shedding status, as well as treatment/baseline HAI status (i.e., by 
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whether pre-vaccination HAI titers were <10 or ≥10).  Effect modification in the immune responses by (i) 
baseline HAI status and (ii) week 1 viral recovery were evaluated using multiplicative interaction terms in 
multilevel mixed-effects linear regressions, that allowed for participant-specific random effects; P values 
indicating the statistical significance of the interaction term are from likelihood ratio tests.  To mitigate the 
potential for false-positive results, a Bonferroni-corrected P value of 0.0007 (i.e., 0.05 ÷ 70) was considered to 
be the threshold for significance.  All P values are from 2-sided statistical tests, and all analyses were performed 
using Stata, version 13.0 (StataCorp LP, College Station, Texas, USA) and R, version 3.2.5.   
 
 
Results 
The relationships between pre-existing immunity, vaccine virus detection, and LAIV-induced humoral 
and mucosal immune responses were examined in an analytical cohort comprising 145 LAIV recipients and 145 
placebo controls, which represented 97% of the participants in the primary study [12].  At baseline, strong 
pairwise correlations were observed for the levels of strain-specific serum immune markers (P<0.0001 for all; 
Supplementary Figure 1).  In each of the three strains, the most highly correlated markers were 
microneutralization and serum IgG (Spearman’s rho:  A/H1N1pdm09, 0.82; A/H3N2, 0.78; B, 0.77).  As reported 
in the companion protocol-defined analyses, viral shedding patterns and immune responses in LAIV recipients 
differed by vaccine strains.  Whereas A/H1N1pdm09 virus was not detected over follow-up, A/H3N2 and B 
vaccine viruses were detected in NPW specimens on one or more days from 46% (N=67/145) and 59% 
(N=86/145) of vaccinees, respectively.  Of note, wild-type B viruses were also detected by Sanger sequencing in 
3 placebo recipients, demonstrating the presence of intercurrent influenza B in circulation in Dhaka at the time 
of the trial.   
Baseline immune marker levels and the odds of not shedding virus upon vaccine receipt 
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In comparing the vaccine recipients in whom virus was detected versus those without virus detection 
for A/H3N2 and B (Table 1), the baseline titers of all of the measured serum immune markers were statistically 
significantly lower in the children from whom virus was detected after LAIV receipt.  To examine the shape of 
the associations more directly, vaccine recipients were grouped into tertiles based on their pre-existing antibody 
titers (Supplementary Table 1), and the odds of being shedding-negative were compared between the groups 
(Figure 1).  Across the panel of serum immune markers, the results consistently indicate the odds of not 
shedding virus upon vaccine receipt increased progressively with each incremental change in pre-existing 
immune titers.  For both A/H3N2 and B mucosal IgA, children in the highest third had approximately 2-fold 
increased odds of being shedding-negative upon LAIV receipt relative to children in the lowest third.    
 
Immune responses to vaccination by treatment and viral shedding status 
 The 145 eligible placebo recipients had no detectable virus and no significant rises in humoral and 
mucosal immune markers between trial days 0 and 21 for either A/H1N1pdm09 (Figure 2) or A/H3N2 (Figure 
3).  In contrast, placebo recipients exhibited statistically significant rises in B-specific serum HAI, likely reflecting 
environmental exposure to wild-type B viruses over follow-up (Figure 4).   
Varying degrees of LAIV immunogenicity were observed for all three strains.  Despite the absence of 
A/H1N1 virus detection after vaccination, LAIV recipients did have marginally higher levels of serum immune 
markers on day 21 than on day 0 (i.e., when measured as a continuous variable rather than by 4-fold rise as 
reported in [13]) (Figure 2).  Serum and mucosal titers for A/H3N2 rose between days 0 and 21 in both the 
shedding-negative and positive groups (Figure 3).  Similarly, with the exception of mucosal IgA levels, B-specific 
immune markers rose statistically significantly after LAIV receipt (Figure 4).  Relative to the serum markers, a 
greater degree of variance was observed in the measures of mucosal IgA for each of the three LAIV viruses. 
Subsidiary analyses demonstrated that there was significant effect modification to the serum immune 
responses between trial days 0 and 21 in children with pre-existing HAI titers below 10 and in those with 
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detectable strain-specific viral shedding.  As illustrated in Supplementary Figure 2, post-vaccination rises in 
A/H3N2-specific HAI, MN, and IgG and B-specific IgG titers were more pronounced in children with baseline 
HAI titers below 10 relative to their peers with baseline HAI titers above 10.  Similarly, post-vaccination rises 
for all A/H3N2-specific serum markers and also for B-specific serum IgG and IgA differed by shedding status, 
such that a greater proportion of children in the shedding-positive groups experienced 4-fold rises than their 
peers in the shedding-negative category (Figure 5).  Cross-sectional analyses from trial day 21 indicate that, 
although the magnitudes of the responses between days 0 and 21 were influenced by shedding category, the 
A/H3N2 titers achieved following vaccination with the LAIV did not differ substantively between the shedding 
and non-shedding groups (Table 1).  For the influenza B component, the day 21 geometric mean titers of the 
serum and mucosal immune markers remained higher in the non-shedders, potentially reflecting some degree of 
pre-existing immunity from prior wild-type infection in the shedding-negative group (Table 1).   
 
Discussion 
The current investigation is an extension of a collaborative international effort to examine safety [13], 
virus shedding and immune responses [13] of Bangladeshi children to a Russian-backbone live, attenuated, intra-
nasally delivered vaccine in a phase II trial. The results presented here provide evidence that vaccinees with 
lower baseline immunity to influenza A/H3N2 and B (i.e., as indicated by lower pre-vaccination antibody titers) 
have significantly higher odds of shedding strain-specific virus in the week after vaccination.  Further, while the 
magnitudes of the A/H3N2 and B-specific immune responses to vaccination were significantly more pronounced 
in participants with detectable vaccine virus shedding (Figure 5), LAIV-induced systemic immune markers to 
A/H3N2 and B influenza also rose statistically significantly in participants with no detectable vaccine virus 
shedding.  Ultimately, the geometric mean titers of serum antibody attained by day 21 in the shedding-positive 
groups were relatively similar to, in the case of A/H3N2, and somewhat lower than, in the case of B, the 
respective shedding-negative groups, which generally started with higher pre-existing antibody titers.  Overall, 
the findings from the A/H3N2 and B influenza strains suggest viral shedding upon LAIV receipt may have greater 
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utility as an indicator of an individual’s immunologic experience than as a generalizable correlate of LAIV 
immunogenicity.   
Given these observations, the lack of A/H1N1pdm09 virus detection despite modest serum antibody 
responses following LAIV receipt is particularly noteworthy.  As high rates of A/H1N1 infections were reported 
in Bangladesh during the 2009 pandemic [15], pre-existing immunity generated from prior natural infection may 
have influenced the trial’s A/H1N1pdm09 results to some degree.  Several pieces of evidence support this 
hypothesis.  First, like those for A/H3N2, the geometric mean titers for A/H1N1pdm09 were consistently higher 
than the titers measured for B at baseline (Table 1).  Second, comparing the density plots of the differences in 
log2 titers between days 21 and 0 across strains (Figure 5), strikingly similar distributions are present in the 
shedding-negative groups for A/H1N1pdm09 and A/H3N2.  Third, the results from a subsequent phase III 
Bangladeshi trial of the same A/H1N1pdm09 Russian-backbone component showed 50% vaccine efficacy for 
A/H1N1pdm09 despite the limited shedding and immune responses measured in this phase II trial [22].  Taken 
together, these findings reinforce the idea that, in the context of recently or currently circulating viruses, some 
clinically relevant immunity may be induced by LAIVs even in the absence of demonstrable virus replication [9, 
21].  Such immune response without detectable virus replication is surprising but has been previously observed 
with respiratory syncytial virus in an animal model [22] and in a human challenge study [23]. Three explanations 
are possible: the first is that replication occurred at a low level or different anatomic site from that sampled, 
second is that the antigenic load presented by the initial dose of vaccine stimulated immunity, or third is that we 
do not yet understand the true correlate(s) of immunity to influenza.  
It is also plausible that additional vaccine-related features, such as strain-specific replicative fitness, 
genetic stability, and/or virus competition for cell receptors, may have contributed to the lack of detectable 
A/H1N1pdm09 replication.  Importantly, good growth of A/H1N1 vaccine virus was originally observed in the 
independently derived Ann Arbor-backbone LAIV [24, 25], that was accompanied by proof of efficacy in United 
States [26].  However, the Ann Arbor A/H1N1 has exhibited a lack of effectiveness [27] leading to 
discontinuation of the CDC recommendation of its use for the 2016-2017 and 2017-2018 influenza seasons in 
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the United States [28].  Although only one direct comparison of safety, infectivity and immunogenicity of the 
A/Ann Arbor and A/Leningrad vaccines has been carried out to date [29], it would appear from this experience 
that the two master strains have a similar level of attenuation.  
The unique analytical approach of this study introduced both strengths and limitations.  As LAIVs do not 
have an established correlate of protection, immunogenicity to influenza has conventionally been evaluated in 
terms of 4-fold rises in serum HAI and/or the achievement of a protective titer—typically at least 40.  Earlier 
research has found, against the backdrop of both vaccine and naturally induced immunity in children in the 
United States, that serum HAI is a poor predictor of susceptibility to A/Ann Arbor vaccine infection [6] and that 
serum antibody generated in response to inactivated vaccine appears to be minimally protective on live vaccine 
challenge [3].  Considering this, we took a different approach in this analysis to evaluate humoral and mucosal 
immune responses as a function of the vaccine or placebo group assignment, the presence or absence of pre-
existing neutralizing antibodies, and the presence or absence of vaccine virus recovery.  While the methods used 
here provide new insight into the findings from Lewis and colleagues by first estimating the associations between 
pre-existing B cell-mediated humoral and mucosal immunity and the odds of viral detection after LAIV 
administration and then comparing the responses of those same immune parameters to vaccination given strain-
specific baseline HAI titers and viral detection, further investigations in other study settings are needed to 
replicate these findings.   In addition to being conducted in a setting, Bangladesh, where enteric pathogens and 
microflora differ from developed country settings [30], the influenza immunity in this population arose 
exclusively from prior exposure to wild type virus. It differs from the experience in the United States where 
correlates of immunity are difficult to measure after exposure to influenza antigens from both natural infection 
and vaccination [6]. Further, whereas mucosal IgA levels measured in stool samples have been previously shown 
to provide a robust indication of vaccine-induced protection in the context of polio (e.g., see [31, 32]), the 
mucosal IgA levels measured in NPW specimens in this study exhibit a high degree of variance that limits their 
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utility; further research is needed to optimize NPW sampling methods and refine the ascertainment of influenza-
specific mucosal IgA. 
In conclusion, the study shows good infectivity and immunogenicity of the A/H3N2 and B Russian-
backbone strains in Bangladesh; particularly in those whose low level of immunity suggested that the LAIV was 
their first influenza exposure. As such, they add to the safety and immunogenicity data supporting the use of 
LAIVs on a global basis.  The results of this study also illustrate that, when viewed alone, neither virus recovery 
nor immunologic response are fully predictive of a protective response to LAIVs.  Even in previously vaccine-
naïve populations, accounting for pre-existing immunity, such as that potentially arising from prior exposure to 
natural infection, is essential for interpreting a LAIV's virologic and immunologic take.     
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Figure Legends. 
Figure 1.  The association between pre-existing immunity (i.e., indicated by tertile of the strain-specific 
immune marker on trial day 0) and subsequent protection from strain-specific viral shedding upon LAIV 
receipt (i.e., indicated by no viral recovery from NPW specimens on trial days 2, 4, and 7) (N=145).  
Odds ratios for being shedding-negative (y-axis) are plotted versus the mean for each tertile of immune marker at 
baseline (x-axis).  The horizontal reference line indicates an odd ratio of 1.  
Figure 2.  A/H1N1pdm09-specific immune responses to placebo (N=145) and LAIV receipt (N=145).  
100% of LAIV recipients were categorized as A/H1N1pdm09 shedding-negative (i.e., indicated by no viral recovery on 
trial days 2, 4, and 7).  The intensity of the color indicates the number of individuals at a given coordinate.  P values are 
from paired t-tests comparing the log2 titers on trial days 0 and 21.  The diagonal reference line indicates equivalence 
between the time points.   
Figure 3.  A/H3N2-specific immune responses to placebo (N=145) and LAIV receipt (N=145).  46% of 
LAIV recipients were categorized as A/H3N2 shedding-negative (i.e., indicated by no viral recovery on trial days 2, 4, 
and 7).  The intensity of the color indicates the number of individuals at a given coordinate.  P values are from paired t-
tests comparing the log2 titers on trial days 0 and 21.  The diagonal reference line indicates equivalence between the 
time points.   
Figure 4.  B-specific immune responses to placebo (N=145) and LAIV receipt (N=145).  59% of LAIV 
recipients were categorized as A/H3N2 shedding-negative (i.e., indicated by no viral recovery on trial days 2, 4, and 7).  
The intensity of the color indicates the number of individuals at a given coordinate.  P values are from paired t-tests 
comparing the log2 titers on trial days 0 and 21.  The diagonal reference line indicates equivalence between the time 
points.   
Figure 5.  Density plots illustrating the distributions of differences in the log2 serum and mucosal 
antibody titers between trial days 0 and 21 by immunoassay, influenza strain, and treatment/shedding 
status (N=290).  P values are from likelihood ratio tests and indicate effect modification of the immune responses by 
shedding status (i.e., shedding-negative versus shedding-positive).  The vertical reference lines indicate four-fold rises 
(i.e., a log2 difference ≥2) between the time points.   
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  Geometric Mean Titer on Day 0, by Tertile 
 Figure 1.  
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  A/H1N1pdm09-specific Log2 Titer on Day 0 
 Figure 2.  
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  A/H3N2-specific Log2 Titer on Day 0 
Figure 3.  
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  B-specific Log2 Titer on Day 0 
Figure 4.  
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  Difference in Log2 Titer between Days 21 and 0 
Figure 5. 
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Table 1.  Cross-sectional comparison of strain-specific serum and mucosal antibody titers on trial days 0 and 21 stratified by viral recovery status in LAIV recipients 
(N=145).  P values are from t-tests of the log2 titers.   
 Day  A/H1N1pdm09  
LAIV Shedding-
negative Group 
(N=145) 
 A/H3N2  
LAIV Shedding-
negative Group 
(N=78) 
A/H3N2  
LAIV Shedding-
positive Group 
(N=67) 
P value, 
between 
shedding 
groups 
 B  
LAIV Shedding-
negative Group 
(N=59) 
B  
LAIV Shedding-
positive Group 
(N=86) 
P value, 
between 
shedding 
groups 
 Geometric Mean 
Titer (95% CI) 
 Geometric Mean Titer (95% CI)  Geometric Mean Titer (95% CI) 
Serum HAI 0  18 (15, 22)  46 (37, 56) 13 (9.8, 16) <0.0001  18 (13, 24) 9.4 (7.7, 11.5) 0.0003 
21  25 (21, 31)  72 (58, 89) 71 (52, 97) 0.93  49 (35, 69) 25 (19, 34) 0.003 
Serum Microneutralization 0  49 (38, 64)  270 (210, 340) 48 (31, 73) <0.0001  49 (29, 53) 8.7 (7.1, 10.6) <0.0001 
21  65 (50, 86)  370 (300, 460) 390 (270, 570) 0.79  86 (63, 120) 34 (25, 48) 0.0002 
Serum Immunoglobulin G 0  4400 (3400, 5600)  8100 (6600, 9800) 1700 (1200, 2500) <0.0001  5800 (4700, 8800) 1100 (860, 1500) <0.0001 
21  6200 (4900, 7800)  10,000 (8600, 11,000) 12,000 (9700, 15,000) 0.13  10,000 (8300, 12,000) 8600 (7100, 10,000) 0.26 
Serum Immunoglobulin A 0  190 (150, 220)  240 (200, 290) 85 (71, 100) <0.0001  230 (180, 430) 92 (80, 110) <0.0001 
21  270 (220, 330)  390 (320, 480) 300 (220, 390) 0.10  440 (340, 570) 350 (280, 450) 0.23 
Mucosal Immunoglobulin A, 
Normalized 
0  0.5 (0.4, 0.6)  0.6 (0.5, 0.8) 0.5 (0.3, 0.6) 0.09  0.5 (0.3, 0.6) 0.4 (0.3, 0.6) 0.63 
21  0.5 (0.4, 0.6)  0.8 (0.6, 1.1) 0.8 (0.6, 1.1) 0.86  0.7 (0.5, 1.0) 0.6 (0.5, 0.9) 0.72 
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